Table 1.
Patient characteristics
| Characteristic | All patients, N=12 |
|---|---|
| Sex | 11 men, 1 woman |
| ECOG PS, median | 1 (range: 0-2) |
| Age, median | 58 y (range: 30-78 y) |
| Histology | 11 (92%) DLBCL |
| 5 (42%) GC* (2 “double hit,” 1 “triple hit”) | |
| 4 (33%) non-GC* | |
| 1 (8%) TRLBCL | |
| 1 (8%) tFL | |
| 1 (8%) FL | |
| Stage | 2 (17%) stage II |
| 10 (83%) stage IV | |
| LDH elevated | 11 (92%) |
| Prior therapies, median | 4 (range: 3-8) |
| Primary refractory† | 9 (75%) |
| Best response to CAR T cells | 9 PD, 3 CR |
| CAR T-cell PFS, median | 2.8 mo (range: 0.4-35.2) |
| Time between CAR T-cell infusion and first pembrolizumab dose | 3.3 mo (range: 0.4-42.8) |
| CD19 expression after CAR T-cell therapy | 9/9 (100%) |
| CAR construct | 8 (75%) murine anti-CD19, 4-1BB, CD3zeta |
| 4 (25%) humanized anti-CD19, 4-1BB, CD3zeta |
FL, follicular lymphoma, grade 1-2; GC, germinal center; DHL, double hit lymphoma; tFL, transformed follicular lymphoma; TRLBCL, T-cell rich large B-cell lymphoma.
*
Germinal center vs nongerminal center cell of origin determined by Hans algorithm.48
†
Primary refractory lymphoma is defined as PD or SD as best response after at least 4 cycles of first-line therapy. Patients must have received an anti-CD20 monoclonal antibody and anthracycline-containing regimen.